Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MPI | P34949 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 3/20 | 0.60 |
| ▸ | THRA | P10827 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512833 | 0.88 | ALDH1A1 (0.84) | KMT2AALDH1A1MAPTLMNAMPI | |
| SCHEMBL12125282 | 0.86 | ALDH1A1 (0.68) | KMT2AALDH1A1MAPTLMNAMPI | |
| SCHEMBL12123647 | 0.85 | ALDH1A1 (0.65) | KMT2AALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL13155199 | 0.84 | ALDH1A1 (0.64) | KMT2AALDH1A1MAPTLMNAMPI | |
| SCHEMBL12123790 | 0.84 | ALDH1A1 (0.73) | KMT2AALDH1A1MAPTLMNAMPI | |
| Hydrochloric Acid SCHEMBL7932182 | 0.82 | ALDH1A1 (0.74) | KMT2AALDH1A1MAPTLMNAMPI | |
| SCHEMBL17886723 | 0.82 | HPGD (0.67) | KMT2AALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL12123771 | 0.81 | ALDH1A1 (0.73) | KMT2AALDH1A1MAPTLMNAMPI | |
| SCHEMBL7255774 | 0.81 | ALDH1A1 (1.00) | KMT2AALDH1A1MAPTLMNAMPI | |
| SCHEMBL12123789 | 0.81 | ALDH1A1 (0.97) | KMT2AALDH1A1MAPTLMNAMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2865381-A1 | ITK inhibitors for treating blood cell malignancies | Pharmacyclics, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | KMT2A 1458/4885ALDH1A1 4370/4885MAPT 3284/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | KMT2A 1458/4885ALDH1A1 4370/4885MAPT 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.